{
    "clinical_study": {
        "@rank": "41723", 
        "acronym": "ADCI002", 
        "arm_group": [
            {
                "arm_group_label": "peri-operative chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Neoadjuvant chemotherapy with 3 cycles of Epirubicin/Cisplatin/5 fluoro-uracil (oral or intra-veinous) Surgery within 3 and 6 weeks after the end of neoadjuvant chemotherapy Adjuvant chemotherapy with 3 cycles of the same chemotherapy within 6 and 12 weeks after surgery"
            }, 
            {
                "arm_group_label": "surgery first with adjuvant chemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Surgery first Adjuvant chemotherapy with 3 cycles of Epirubicin/Cisplatin/5FU within 6 and 12 weeks after surgery No neoadjuvant chemotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The ADCI 002 trial is a large multicenter phase II-III prospective randomized controlled\n      trial comparing primary surgery versus primary chemotherapy followed by surgery in patients\n      with a resectable signet ring cell gastric adenocarcinoma"
        }, 
        "brief_title": "Multicenter Trial to Evaluate the Strategy of Primary Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma", 
        "completion_date": {
            "#text": "October 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Resectable Signet Ring Cell Gastric Adenocarcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Stomach Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adenocarcinoma of the stomach or the oesogastric junction of type III of Siewert\n             classification,histologically proven with the presence of signet ring cells\n             (according to WHO 2000 classification) or diffuse form (according to Lauren\n             classification) on pre-therapeutic biopsies\n\n          -  tumoural stage IB, II or III (according to UICC-AJCC 2009)\n\n          -  patient judged resectable in a curative intent on inclusion\n\n          -  absence of distant metastasis\n\n          -  absence of peritoneal carcinomatosis during pre-treatment explorative laparoscopy\n\n          -  WHO performance status 2 or less\n\n          -  age over 18 or under 80 years\n\n          -  weight loss at the time of inclusion < 15%\n\n          -  neutrophilic polynuclears more than 1500/mm3\n\n          -  platelets more than 100000/mm3\n\n          -  creatinine clearance more than 50 ml/min\n\n          -  serum-albumin more than 30 gram/l\n\n          -  bilirubin less than 1,5 normal\n\n          -  prothrombin rate over 80%\n\n          -  absence of prior treatment with chemotherapy or radiotherapy for gastric cancer\n\n          -  absence of kniwn child B or C cirrhosis\n\n          -  left ventricular ejection fraction more than 50% before epirubicin treatment\n\n          -  extension check-up performed within 4 weeks of inclusion\n\n          -  signed written informed consent given by the patient\n\n        Exclusion Criteria:\n\n          -  no corresponding to the inclusion criteria\n\n          -  another malignant tumour treated for curative purposes during the past 5 years\n             excepted basocellular skin carcinoma or in situ uterine cervix cancer\n\n          -  allergy to the active substance or one of the excipients in the study drugs\n\n          -  pregnancy or breast-feeding\n\n          -  any other concommitant treatment, immunotherapy or hormonal therapy\n\n          -  history of abdominal or chest radiotherapy\n\n          -  any evolving disorder which is not under control (liver failure, kidney failure,\n             respiratory failure, evolving heart failure or myocardial necrosis during the past 6\n             months)\n\n          -  patients who cannot be regularly monitored"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "314", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01717924", 
            "org_study_id": "A120566-21"
        }, 
        "intervention": [
            {
                "arm_group_label": "peri-operative chemotherapy", 
                "description": "Usual treatment strategy for gastric adenocarcinoma", 
                "intervention_name": "peri-operative chemotherapy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "surgery first with adjuvant chemotherapy", 
                "description": "strategy with a surgical procedure first, without the usual peri-operative chemotherapy", 
                "intervention_name": "Surgery first", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Signet ring cell", 
            "gastric adenocarcinoma", 
            "peri-operative chemotherapy", 
            "surgery"
        ], 
        "lastchanged_date": "August 21, 2013", 
        "location": {
            "contact": {
                "email": "christophe.mariette@chru-lille.fr", 
                "last_name": "christophe mariette, MD,PhD", 
                "phone": "+33320444407"
            }, 
            "facility": {
                "address": {
                    "city": "Lille cedex", 
                    "country": "France", 
                    "zip": "59037"
                }, 
                "name": "General and digestive surgical department, Claude Huriez Hospital, University Hospital"
            }, 
            "investigator": {
                "last_name": "christophe mariette", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter Randomized Controlled Trial to Evaluate the Strategy of Primary Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma (ADCI002 Study)", 
        "overall_contact": {
            "email": "christophe.mariette@chru-lille.fr", 
            "last_name": "christophe Mariette, MD,PhD", 
            "phone": "+33320444407"
        }, 
        "overall_official": {
            "affiliation": "FFCD, FNCLCC, FRENCH", 
            "last_name": "christophe mariette, MD,PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of patients dead in the 2-years", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01717924"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital, Lille", 
            "investigator_full_name": "Christophe MARIETTE", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Disease-free survival at 2 years", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Disease-free survival at 3 years", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Overall survival at 3 years", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "R0 resection rate", 
                "safety_issue": "No", 
                "time_frame": "within 1 year"
            }, 
            {
                "description": "tolerance will be measured by the rate and grade of chemotherapy's complications", 
                "measure": "grade III/IV toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "post operative morbi-mortality", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Average of patients who benefit from the overall treatment strategy", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "quality of life", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "It will be assessed by quality of life questionnaire(QLQ-C30, QLQ-STO-22,SF-36) and emotional status questionnaire(CES-D, STAI-Y-A, Brief-IPQ, WCC, ICEC-R, CRA)", 
                "measure": "emotional status", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "University Hospital, Lille", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Federation Francophone de Cancerologie Digestive", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "UNICANCER", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "F\u00e9d\u00e9ration de Recherche en Chirurgie (FRENCH)", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University Hospital, Lille", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}